Blueprint
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 14C
Information Statement Pursuant to Section 14(c)
of the Securities Exchange Act of 1934
Check
the appropriate box:
☒
Preliminary
Information Sheet
☐
Confidential, for
Use of the Commission Only (as permitted by Rule 14c-5(d)(2)
)
☐
Definitive
Information Statement
WOUND MANAGEMENT TECHNOLOGIES, INC.
(Exact
name of registrant as specified in its Charter)
Payment
of Filing fee (Check the appropriate box):
☐
Fee computed on
table below per Exchange Act Rules 14c-5(g) and 0-11
1)
Title of each class
of securities to which transaction applies:
2)
Aggregate number of
securities to which transaction applies:
3)
Per unit price or
other underlying value of transaction computed pursuant to Exchange
Act Rule 0-11 (set forth the amount on which the filing fee is
calculated and state how it was determined):
4)
Proposed maximum
aggregate value of transaction:
☐
Fee paid previously
with preliminary materials.
☐
Check box if any
part of the fee is offset as provided by Exchange Act Rule
0-11(a)(2) and identify the filing for which the offsetting fee was
paid previously. Identify the previous filing by registration
number, or the Form or Schedule and the date of its
filing.
1)
Amount Previously
Paid:
2)
Form Schedule or
Registration Statement No.:
WOUND MANAGEMENT TECHNOLOGIES, INC.
1200 Summit Ave, Suite 414
Fort Worth, Texas 76102
INFORMATION STATEMENT
WE ARE NOT ASKING YOU FOR A PROXY
AND YOU ARE REQUESTED NOT TO SEND US A PROXY
INTRODUCTION
This
Information Statement (the “Information Statement”)
is being furnished to the holders of shares (the
“Shareholders”)
of common stock, par value $0.001 per share (the
“Common
Stock”), of Wound Management Technologies, Inc. (the
“Company”). We are
sending you this Information Statement to notify you that on March
21, 2019, shareholders holding a majority of our capital stock
entitled to vote (the “Majority Shareholders”)
approved by written consent in lieu of a meeting of shareholders an
amendment to the Company’s Certificate of Formation (the
“Amendment”) to accomplish
the following actions (the “Corporate
Actions”):
(1) the
effectuation of a 1-for-100 reverse stock split of the
Company’s outstanding Common Stock such that every
Shareholder shall receive one share of Common Stock for every 100
shares of Common Stock held (the “Reverse Stock
Split”);
(2) upon
the effectiveness of the Reverse Stock Split, the reduction of the
authorized capital stock of the Company to 20,000,000 shares of
Common Stock and 2.000,000 shares of preferred stock;
and
(3) the
change of the name of the Company to: Sanara MedTech,
Inc.
The
written consent of the Majority Shareholders constitutes the
required approval of the Company’s Shareholders and is
sufficient under the Texas Business Organizations Code (the
“TBOC”)
and the Company’s Certificate of Formation and Bylaws to
approve the Corporate Actions described above. No further action is
required from the remaining Shareholders. Accordingly, the
Corporate Actions are not being submitted to these other
Shareholders for a vote. This Information Statement is being sent
to you as required by Section 6.202(d) of the TBOC and Section
14(c) of the Securities Exchange Act of 1934, as amended, and
Regulation 14C thereunder.
THIS
INFORMATION STATEMENT IS BEING FURNISHED TO YOU IN ACCORDANCE WITH
THE TEXAS BUSINESS ORGANIZATIONS CODE AND FEDERAL SECURITIES LAW
SOLELY FOR THE PURPOSE OF INFORMING YOU OF THE CORPORATE ACTIONS
THAT HAVE BEEN APPROVED AND THAT WILL OCCUR IF THE ACTIONS ARE
COMPLETED.
NO
SHAREHOLDER MEETING WILL BE HELD TO CONSIDER THESE MATTERS. WE ARE
NOT SOLICITING YOUR VOTE, AND YOU ARE REQUESTED NOT TO SEND A VOTE
BY PROXY.
This
Information Statement is being first sent to Shareholders on or
about April __, 2019. The Corporate Actions will not become
effective until at least 20 calendar days after the date this
Information Statement is first mailed to Shareholders
The
entire cost of furnishing this Information Statement will be borne
by the Company. We will request brokerage houses, nominees,
custodians, fiduciaries and other like parties to forward this
Information Statement to the beneficial owners of the Common Stock
held of record by them.
APPROVAL OF THE CORPORATE ACTIONS
On
March 20, 2019 the Board of Directors approved the Corporate
Actions and set the close of business on March 20, 2019 as the
“record date” for purposes of determining the number of
shares of stock outstanding and the shareholders entitled to vote
on the approval of the Corporate Actions. Each share of outstanding
Common Stock is entitled to one vote on matters submitted to
shareholders. Each share of outstanding Series F Convertible
Preferred Stock (the “Series F Preferred
Stock”) is entitled to 200 votes on matters submitted
to shareholders. On the record date the Company had outstanding
236,643,185 shares of Common Stock and 1,136,815 shares of Series F
Preferred Stock.
Section
6.202 of the TBOC provides that the certificate of formation of a
company may authorize the shareholders of the company to take
action without holding a meeting, providing notice, or taking a
vote if shareholders of the company, who have at least the minimum
number of votes that would be necessary to take the action at a
meeting in which each shareholder entitled to vote on the action is
present and votes, instead sign a written consent or consents
stating the action taken. Article Nine of the Company’s
Certificate of Formation contains such provision permitting
shareholder action by written consent of the Company’s
shareholders.
Unless
otherwise provided in the TBOC, an amendment of a
corporation’s certificate of formation requires the approval
of shareholders of at least two-thirds of the outstanding shares
entitled to vote on the action Section 21.365 of the TBOC provides
that as to a matter for which the affirmative vote of the holders
of a specified potion of the shares of a class or series is
required, the certificate of formation may provide that the
affirmative vote of the holders of a specified portion, but not
less than the majority, of the shares of the class or series is
required for action of such holders on that matter. Article Seven
of the Company’s Certificate of Formation provides that
approval of any action of shareholders under the TBOC requiring the
affirmative vote of any specified portion of the shares of the
Company will require the approval of shareholders of a majority of
the Company’s shares entitled to vote on the
action.
In
order to eliminate the costs and management time involved in
holding a special meeting of shareholders and to avoid the expense
associated with mailing and soliciting proxies for a shareholder
vote on the Corporate Actions, the Board of Directors determined to
obtain approval of shareholders by written consent. Holders of
outstanding Common Stock and Series F Preferred Stock are entitled
to vote on the Corporate Actions and are counted together as a
single class. Holders of outstanding Common Stock are entitled to
236,643,185 votes, and holders of outstanding Series F Preferred
Stock are entitled to 227,363,000 votes. The Board of Directors
authorized the Corporate Transactions if (i) shareholders
representing a majority of votes entitled to vote approve the
transaction and (ii) holders of a majority of the outstanding
shares of Common Stock approved the transaction.
On
March 21, 2019, (i) shareholders of record of Common Stock
representing 121,914,878 votes executed the written consent
approving the Corporate Actions and (ii) shareholders of record of
Series F Preferred Stock representing 227,363,000 votes executed
the written consent approving the Corporate Actions, which together
total 349,277,878 votes approving the Corporate Actions out of
464,006,185 votes entitled to be voted, or 75% of shares entitled
to vote. The holders of the 121,914,878 shares of Common Stock that
approved the Corporate Actions, constituted a majority of
outstanding shares of Common Stock.
At any
time before the Company’s filing with the Secretary of State
of the State of Texas of the Company’s certificate of
amendment to its Certificate of Formation (the “Certificate of
Amendment”) becomes effective to effectuate the
Corporate Actions, the Board of Directors may abandon the Corporate
Actions without further action by Shareholders notwithstanding the
prior authorization by written consent of the Company’s
shareholders. The form of the Amendment to our Certificate of
Formation that would effect the Corporate Actions is attached to
this Information Statement as Appendix A.
Effective Time of the Corporate Actions
The
Company intends to file with the Secretary of State of the State of
Texas, as soon as practicable on or after the 20th day after this
Information Statement is first sent to Shareholders, the
Certificate of Amendment effectuating the Corporate Actions. Unless
a later time is specified, such Certificate of Amendment will
become effective at the close of business on the date it is
accepted for filing by the Secretary of State. It is presently
contemplated that the Corporate Actions will become effective
approximately 20 days from the date that this Information Statement
is first sent to Shareholders. The text of the Certificate of
Amendment is subject to modification to include such changes as may
be required by the Secretary of State of Texas to effectuate the
Corporate Actions.
No Appraisal Rights for the Reverse Stock Split
Under the
TBOC and the Company’s Certificate of Formation and Bylaws,
Shareholders are not entitled to appraisal rights with respect to
the Reverse Stock Split.
THE CORPORATE ACTIONS
Reverse Stock Split
The
Board of Directors has determined that it is in the best interest
of the Shareholders to effectuate the Reverse Stock Split of our
issued and outstanding Common Stock, which will change and
reclassify the Common Stock such that every Shareholder will
receive one share of Common Stock for every 100 shares of Common
Stock held. To the extent that the number of shares of Common Stock
held by a Shareholder is not evenly divisible by 100, no fractional
share will be issued as a result thereof. In lieu of the issuance
of a fraction of a share to any Shareholder, the Company will pay
to such Shareholder a cash payment in the amount equal to such
fraction amount of one share of Common Stock otherwise issuable
thereby, multiplied by the average of the high and low prices of
the Common Stock as traded in the OTCQB market of the OTC Markets
Group on the day immediately following the day the Reverse Stock
Split is made effective by the appropriate securities regulatory
authority.
The
Stock Split will affect all of the holders of Common Stock
uniformly. Upon the effectiveness of the Reverse Stock Split, each
Shareholder will own a reduced number of shares of our Common
Stock, but will hold the same percentage of the outstanding Common
Stock and voting power as the Shareholder held prior to the
Effective Date, except for the small effect of any cash payment
received in lieu of a fractional share. For Shareholders owning a
small number of shares, any cash payment in lieu of a fractional
share could have a disproportionate effect relative to Shareholders
having larger share holdings. Shareholders who currently own fewer
than 100 shares will receive a cash payment in lieu of a fraction
of a share and will then cease to be Shareholders.
The
Reverse Stock Split will take effect with the effectiveness of the
Company’s filing of the Certificate of Amendment. The Company
reserves the right not to file the Certificate of Amendment and
effect the Reverse Stock Split if the Board of Directors determines
it not to be in the best interests of the Company and the
Shareholders.
Upon
effectiveness of the Reverse Stock Split, the par value of the
Common Stock will remain the same at $0.001 per share, the stated
capital on the Company’s balance sheet will be reduced in
proportion with the Reverse Stock Split, and the additional paid-in
capital account will be credited with such reduction. These
accounting entries will have no impact on total shareholders’
equity. The Company’s per share net income/loss and per share
net book value will be increased in proportion to the Reverse Stock
Split because of the reduction in the number of shares that will be
outstanding.
After
the Reverse Stock Split becomes effective, the Company will adjust
the conversion rights and the voting rights of the Company’s
Series F Convertible Preferred Stock in proportion to the Reverse
Stock Split. In place of the right to convert each share of Series
F Preferred Stock into 200 shares of Common Stock, each holder will
have the right to convert each share of Series F Preferred Stock
into 2 shares of Common Stock after the Reverse Stock Split becomes
effective. Each share of Series F Preferred Stock entitles the
holder to the number of votes that may be voted for the shares of
Common Stock into which it is convertible. Consequently, after the
Reverse Stock Split each share of Preferred Stock will entitle the
holder to 2 votes, to be counted together with the votes of the
holders of Common Stock, on matters submitted to a vote of
shareholders of the Company.
The
Company will also make proportionate adjustments to the per share
exercise price and the number of shares issuable upon the exercise
of all outstanding employee stock options, which will result in
approximately the same aggregate exercise price being paid to
exercise a proportionately reduced number of options as was in
effect immediately before the Reverse Stock Split. The current
maximum number of shares that may be issued under our current
employee stock incentive plans will also be proportionately
reduced.
Reasons for the Board’s Decision
The
Board of Directors believes that the current low per-share market
price of the Common Stock reflects an undervaluation of the true
value of the Company’s business and adversely affects the
Company’s ability to raise additional working capital to fund
faster growth of its business. The Board of Directors believes that
the current low per-share market price of the Common Stock lessen
the suitability of the Common Stock to certain members of the
investing public, including institutional investors, and may
negatively affect the perception of the Company as a viable
business enterprise. Many institutional investors have policies
prohibiting lower-priced stocks in their portfolios, which reduces
the number of potential buyers of the Common Stock. Additionally,
securities analysts at many brokerage firms are reluctant to
recommend lower-priced stocks to their clients or to monitor
companies with lower-priced stocks.
The
Common Stock currently is not listed on any stock exchange and is
only traded in the over-the-counter market. The low per-share price
of the Common Stock is a principal reason the Common Stock is not
eligible for listing on a national stock exchange. Many securities
analysts only follow companies and recommend stocks that are traded
on a stock exchange. The ability to list the Common Stock on a
stock exchange would provide greater visibility of the Company and
its Common Stock to the investing public.
The
Board of Directors believes that the above factors together tend to
reduce market demand for the Common Stock and perpetuate the
market’s low valuation of the Company’s business. The
Board of Directors believes that the Reverse Stock Split should
have the immediate effect of increasing the per-share price of the
Common Stock and would contribute to an increase in the appeal of
the Common Stock to the financial community and investing public.
This increase in stock price may also allow the Board to take other
measures that would enable the future listing of the Common Stock
on a stock exchange with a view to potentially improving the
Company’s market valuation and ability to raise capital.
There is no assurance, however, that the Reverse Stock Split will
have a significant positive impact on the market price of the
Common Stock or improve the Company’s ability to raise
capital and finance its business operations.
Federal Income Tax Consequences of the Reverse Stock
Split
The
following is a summary of certain material federal income tax
consequences of the Reverse Stock Split to a beneficial owner of
Common Stock that is a citizen or individual resident of the United
States, a corporation organized in or under the laws of the United
States or any state thereof or the District of Columbia or
otherwise subject to U.S. federal income taxation on a net income
basis relating to the Common Stock (a “U.S. holder”). A trust
may also be a U.S. holder if (1) a U.S. court is able to exercise
primary supervision over administration of such trust and one or
more U.S. persons have the authority to control all substantial
decisions of the trust or (2) it has a valid election in place to
be treated as a U.S. person. This summary assumes that the shares
of Common Stock prior to the Reverse Stock Split were, and the
shares of Common Stock after to the Reverse Stock Split will be,
held as a “capital asset,” as defined in the Internal
Revenue Code of 1986, as amended (i.e., generally, property held
for investment). This summary does not purport to be a complete
discussion of all of the possible federal income tax consequences
of the Reverse Stock Split and is included for general information
only. Further, it does not address any state, local or foreign
income or other tax consequences, nor does it address the tax
consequences to holders that are subject to special tax rules, such
as banks, insurance companies, regulated investment companies,
personal holding companies, foreign entities, nonresident alien
individuals, broker-dealers and tax-exempt entities.
The
information in this summary is based on the provisions of the
Internal Revenue Code of 1986, as amended, final and temporary U.S.
Treasury regulations, administrative interpretations and practices
of the Internal Revenue Service, including its practices and
policies as endorsed in private letter rulings, which are not
binding on the Internal Revenue Service except in the case of the
taxpayer to whom a private letter ruling is addressed, and existing
judicial authority, all as in effect as of the date of this
Information Statement. Future legislation, regulations,
administrative interpretations, and court decisions could change
current law or adversely affect existing interpretation of current
law. Any change could apply retroactively. We have not obtained any
rulings from the Internal Revenue Service concerning the tax
treatment of the Reverse Stock Split. Therefore, it is possible
that the Internal Revenue Service could challenge the statements in
this summary, which do not bind the Internal Revenue Service or the
courts, and that a court could agree with the Internal Revenue
Service. Each Shareholder is urged
to consult with such Shareholder’s own tax advisor with
respect to the U.S. federal, state and foreign income and other tax
consequences of the Reverse Stock Split.
The
Reverse Stock Split should be treated as a recapitalization for
U.S. federal income tax purposes. Therefore, a Shareholder
generally will not recognize gain or loss on the Reverse Stock
Split, except to the extent of cash, if any, received in lieu of a
fractional share interest in the post-Reverse Stock Split shares.
In general, the aggregate tax basis of the post-split shares
received will be equal to the aggregate tax basis of the pre-split
shares exchanged (excluding any portion of the holder’s basis
allocated to fractional shares), and the holding period of the
post-split shares received will include the holding period of the
pre-split shares exchanged. A holder of the pre-split shares who
receives cash will generally recognize gain or loss equal to the
difference between the portion of the tax basis of the pre-split
shares allocated to the fractional share interest and the cash
received. Such gain or loss will be a capital gain or loss and will
be short term if the pre-split shares were held for one year or
less and long term if held more than one year. No gain or loss will
be recognized by the Company us as a result of the Reverse Stock
Split. The deductibility of net capital losses by individuals and
corporations is subject to limitations. U.S. holders that have
acquired different blocks of our Common Stock at different times or
at different prices are urged to consult their tax advisors
regarding the allocation of their aggregate adjusted basis among,
and the holding period of, our Common Stock.
Change
of Company Name and Capitalization
In
conjunction with the Company’s strategic business plan to
operate in the wound care and surgical treatment areas, the Board
of Directors believes that changing the Company’s name to
“Sanara MedTech, Inc.” will better align and associate
the Company’s business and products with the new name. The
change of name will not change the terms of the Common Stock or the
rights of holders with respect to their ownership of shares of
Common Stock.
The
Reverse Stock Split itself will not change the authorized shares of
stock that the Company can issue. The Board of Directors believes
it is appropriate to reduce of the number of shares of Common Stock
and Preferred Stock that the Company is authorized to issue which
takes into account the Reverse Stock Split. In doing so, the Board
wants to ensure that the Company will have the capacity to issue
Common Stock in the future to raise additional equity capital to
grow the Company’s operations, including through potential
acquisition transactions. Future issuances of Common Stock, which
the Board of Directors may determine is in the best interest of the
Company and its shareholders, may be necessary to fund employee
incentive equity compensation arrangements and deal with future
unanticipated events. The Board of Directors has the authority to
issue additional shares of Common Stock for corporate purposes
without further action by Shareholders. At favorable market prices
of the Common Stock, the Company will consider issuing additional
Common Stock to finance the capital needs for the growth of its
business. This reduction in the number of authorized shares of
Common Stock, as compared to the change in the number of
outstanding shares that will result from the Reverse Stock Split,
will not immediately affect the rights of the current Shareholders.
Any future issuance of additional Common Stock would have a
dilutive effect on current ownership of Shareholders.
On
March 20, 2019, there were 236,643,185 shares of Common Stock and
1,136,815 shares of Series F Preferred Stock issued and
outstanding. Following the Reverse Stock Split and the decrease in
the authorized capital stock, the Company will have authorized
capital stock consisting of 20,000,000 shares of Common Stock, of
which approximately 2,366,000 shares will be issued and outstanding
with approximately 211,000 shares reserved for issuance upon
conversion of existing convertible debt and the exercise of
outstanding employee stock options. The authorized capital stock
will also consist of 2,000,000 shares of Preferred Stock, of which
1,136,815 shares of Series F Preferred Stock will be issued and
outstanding.
PROCEDURES FOR SHAREHOLDERS
Shareholders with Certificates
Shareholders
holding certificates for their shares of Common Stock will be sent
a transmittal letter by our stock transfer agent after the Reverse
Stock Split becomes effective. The letter of transmittal will
contain instructions on how to surrender your certificate(s) to the
transfer agent in exchange for certificates representing the
appropriate number of whole shares after the Reverse Stock Split.
No new certificates will be issued to a Shareholder until all of
his/her old certificates, together with a properly completed and
executed letter of transmittal, have been received by the stock
transfer agent. No Shareholder will be required to pay a transfer
or other fee to exchange his/her old certificates. Shareholders
will then receive a new certificate(s) representing the number of
whole shares of Common Stock resulting from the Reverse Stock Split
and a check in lieu of a fractional share, if any fractional share
would have resulted from the Reverse Stock Split. Until surrendered
to our transfer agent, the old certificate(s) held by each
Shareholder will represent only the number of whole shares of
Common Stock resulting from the Reverse Stock Split. Any old
certificate submitted for exchange, whether because of a sale,
transfer or other disposition of the stock represented by that
certificate, will automatically be exchanged for a new certificate.
New certificates will contain the same restrictive legend, if any,
that is on the back of the corresponding old certificate.
Shareholders should not destroy any stock certificate(s) and
should not submit any stock certificate(s) until requested to do
so.
Beneficial Holders of Common Stock through Brokers,
etc.
We will
instruct brokers, banks, custodians or other nominees of
Shareholders to effect the Reverse Stock Split for their beneficial
holders who hold Common Stock in street name. However, these
brokers, banks, custodians or other nominees may have different
procedures for processing the Reverse Stock Split than the
procedures of our stock transfer agent. Shareholders who hold
shares with a broker, bank, custodian or other nominee and who have
any questions in this regard are encouraged to contact their banks,
brokers, custodians or other nominees.
DESCRIPTION OF CAPITAL STOCK
Description of Common Stock
Number of Shares. The Company’s
Certificate of Formation currently authorizes the issuance of
250,000,000 shares of Common Stock, $0.001 par value per share, of
which 236,643,185 shares were outstanding on March 20, 2019. Upon
the effectiveness of the Corporate Actions the Certificate of
Formation will be amended to provide for 10,000,000 shares of
Common Stock, of which approximately 2,366,400 shares will be
outstanding. All of the outstanding shares of Common Stock are
fully paid and non-assessable. No preemptive rights are available
to Shareholders to purchase shares of Common Stock.
Voting Rights. Holders of shares of
Common Stock are entitled to one vote for each share held of record
on all matters to be voted on by Shareholders. The Certificate of
Formation provides that approval of any action of shareholders
under the TBOC requiring the affirmative vote of any specified
portion of the shares of the Company will require the approval of
shareholders of a majority of the Company’s shares entitled
to vote on the action. Accordingly, the holders of a simple
majority of the aggregate number of shares of Common Stock and
votes entitled to holders of the Series F Preferred Stock will be
able to elect the directors of the Company and, except in very
limited circumstances specified in the TBOC, approve or disapprove
any other matter submitted to a vote of Shareholders.
Dividends. The holders of Common Stock
are entitled to receive ratably such dividends, if any, as may be
declared by the Board of Directors out of funds legally available.
We have not paid any dividends since our inception, and we
presently anticipate that all earnings, if any, will be retained
for development of our business. Any future declaration of
dividends will be at the discretion of the Board of Directors and
will depend upon, among other things, our future earnings,
operating and financial condition, capital requirements, and other
factors.
Description of Preferred Stock
General. The Company’s
Certificate of Formation currently authorizes the issuance of
5,000,000 shares of preferred stock from time to time in one or
more series. Currently 1,136,815 shares of Series F Convertible
Preferred Stock are issued and outstanding. Upon effectiveness of
the amendment to the Company’s Certificate of Formation, the
Company will be authorized to issue 2,000,000 shares of preferred
stock, which may be issued in one or more series from time to time
by the Board of Directors. The Board of Directors is authorized to
determine, prior to issuing any such series and without any vote or
action by the shareholders, the rights, preferences, privileges and
restrictions of the shares of such series, including, the
preferences and relative rights among each series, dividend rights,
voting rights, terms of redemption, retirement or any sinking fund,
conversion and exchange rights, and the preferences upon any
distribution of the assets resulting from the liquidation or
winding up of the Company. The Board of Directors has no current
intent to issue any additional series of preferred
stock.
Series F Convertible Preferred
Stock.
Number, Rank, Dividends. The Series F Preferred Stock
consists of 1,200,000 authorized shares, of which 1,136,815 shares
are outstanding. Shares of Series F Preferred Stock rank prior to
the payment of dividends and the distribution of assets upon the
liquidation or winding up of the Company. Each share of Series F
Preferred Stock is entitled to the amount of dividends payable on
200 shares of Common Stock, and upon the liquidation or winding up
of the Company an amount equal to $5.00 per share of Series F
Preferred Stock.
Conversion. Each share of Series F
Preferred Stock is presently convertible at any time at the option
of the holder into 200 shares of Common Stock for each full share
of Series F Preferred Stock held. If the Company pays a dividend or
distribution on its Common Stock in shares of Common Stock, or
subdivides or combines the outstanding Common Stock, then the
Company will adjust the conversion rate of the Series F Preferred
Stock so that thereafter upon conversion the holder of the Series F
Preferred Stock will be entitled to receive the number of shares of
Common Stock receivable as if the conversion had been made prior to
such event. After the Reverse Stock Split, each share of Series F
Preferred Stock will be convertible into 2 shares of Common
Stock.
In the
case of any reclassification of the Common Stock, or a merger,
consolidation or sale of substantially all of the assets of the
Company, or any compulsory share exchange in which Common Stock is
converted into other securities, cash or other property, then as
part of the terms of such transaction each share of Series F
Preferred Stock then outstanding would have the right to convert
such share only into the kind and amount of securities, cash and
other property receivable upon such reclassification,
consolidation, merger, sale, or share exchange by a holder of the
number of shares of Common Stock of the Corporation into which such
share of Series F Preferred Stock might have been
converted.
Voting. The holder of each share of
Series F Preferred Stock is entitled to vote on all matters
submitted for a vote of Company shareholders. Each share entitles
the holder to the number of votes equal to the number of shares of
Common Stock into which the Series F Preferred Stock could be
converted at the record date for determination of the shareholders
entitled to vote on the matter, with the votes being counted
together with the votes of the holders of Common
Stock.
COMMON STOCK OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND
MANAGEMENT
The
following table sets forth as of the record date certain
information regarding beneficial ownership of our Common Stock by
(1) each person who is known by us to beneficially own more than 5%
of our Common Stock, (2) each of our officers and directors and (3)
all of our officers and directors as a group. The last known
address of each person other than CGI Cellerate RX, LLC is 1200
Summit Ave., Suite 414, Fort Worth, Texas 76102. On the record date
there were 236,643,185 shares of Common Stock issued and
outstanding.
Name
of
Owner
|
Number
of Shares
Beneficially
Owned
|
Percentage
of
Common
Stock
|
James
W. Stuckert
|
76,086,287
(a)
|
16.4%
|
S. Oden
Howell
|
42,292,429
(b)
|
9.1%
|
CGI
Cellerate RX, LLC (c)
|
244,322,339
(d)
|
52.6%
|
J.
Michael Carmena
|
166,667
(e)
|
*
|
Michael
D. McNeil
|
33,333
(e)
|
*
|
Officers
and Directors as a group (5 persons)
|
362,901,055
|
78.2%
|
__________________
(a)
Mr. Stuckert holds
sole voting and investment power over 67,470,887 shares and shared
voting and investment power over 8,615,400 shares.
(b)
Mr. Howell holds
sole voting and investment power over all shares.
(c)
Ron Nixon is a
director of the Company and a manager of Catalyst Rochal, LLC.
Catalyst Rochal, LLC, Ron Nixon and Brad Gurasich may be deemed to
share beneficial ownership and voting and investment power with CGI
Cellerate RX, LLC through a relationship of control of CGI
Cellerate RX, LLC. The last known address of CGI Cellerate, LLC is
1375 Enclave Parkway, Houston, TX 77077.
(d)
Represents
16,959,339 shares issuable upon full conversion of the principal
amount of the Company’s convertible promissory note as of
December 31, 2018 and 227,363,000 shares issuable upon conversion
of the outstanding Series F Preferred Stock, in each case held by
CGI Cellerate RX, LLC.
(e)
Shares that may be
acquired upon exercise of employee stock options that are
exercisable within 60 days.
DELIVERY OF INFORMATION TO A SHARED ADDRESS
If you and
one or more Shareholders share the same address, it is possible
that only one Information Statement was delivered to your address.
Any registered Shareholder who wishes to receive a separate copy of
the Information Statement at the same address now or in the future
may mail a request to receive separate copies to the Company at
1200 Summit Ave., Suite 414, Fort Worth, Texas 76102, Attn: CFO, or
call the Company at (817) 529-2300 and we will promptly deliver the
Information Statement to you upon your request. Shareholders who
received multiple copies of this Information Statement at a shared
address and who wish to receive a single copy may direct their
request to the same address.
This
Information Statement is provided to the Shareholders of the
Company only for information purposes in connection with the
Corporate Actions, in accordance with Rule 14c-2 of the Securities
Exchange Act of 1934. Please carefully read this Information
Statement.
ADDITIONAL INFORMATION
The
Company is subject to the disclosure requirements of the Securities
Exchange Act of 1934, as amended, and in accordance therewith, file
reports, information statements and other information, including
annual and quarterly reports on Form 10-K and 10-Q, with the
Securities and Exchange Commission (the “SEC”). Reports
and other information filed by the Company can be inspected and
copied at the public reference facilities maintained by the SEC at
100 F Street, NE, Washington, DC 20549. In addition, the SEC
maintains a web site on the Internet (http://www.sec.gov) that
contains reports, information statements and other information
regarding issuers that file electronically with the SEC through
EDGAR, the Electronic Data Gathering, Analysis and Retrieval
System.
April __,
2019
By Order of the
Board of Directors
/s/ Michael
Carmena
Michael
Carmina
Chief
Executive Officer
APPENDIX A
FORM OF AMENDMENT OF CERTIFICATE OF FORMATION
Article
One of the Certification of Formation shall be amended to
state:
The
name of the Corporation is “Sanara MedTech,
Inc.”
Article
Four of the Certification of Formation shall be amended to state in
its entirety as follows:
(a)
Authorized Capital
Stock. The total number of shares of capital stock that the
Corporation shall be authorized to issue is 22,000,000 shares, of
which 20,000,000 shares will be Common Stock, par value $0.001 per
share, and 2,000,000 shares of which will be Preferred Stock, par
value $10.00 per share.
Preferred Stock may
be issued from time to time in one or more series as may be
determined from time to time by the Board of
Directors. The Board of Directors is hereby authorized,
subject to any prohibitions set forth in any series of Preferred
Stock of the Corporation, to set the number of shares constituting
each series and to fix or alter the rights, preferences, privileges
and restrictions of each series, including, the preferences and
relative rights among each series, dividend rights, voting rights,
terms of redemption, retirement or any sinking fund, conversion and
exchange rights, and the preferences upon any distribution of the
assets of the Corporation in the liquidation or winding up of the
Corporation. The Board of Directors is authorized to increase or
decrease the number of shares of any such series subsequent to the
issuance of shares of that series, but not below the number of
shares of such series then outstanding. In case the
number of shares of any series shall so be decreased, the shares
constituting such decrease shall resume the status that they had
prior to the adoption of the resolution originally fixing the
number of shares of such series.
(b)
Common Stock Reverse
Split. Effective as of the effective date set forth under
Effectiveness of Filing of this Amendment to the Certificate of
Formation (or in the absence of such date, on the date this
Amendment to the Certificate of Formation is filed with the
Secretary of State of Texas) (the “Effective Time”), a
1-for-100 reverse stock split of the Common Stock will be
effectuated such that every 100 shares of Common Stock issued and
outstanding immediately prior to the Effective Time (the “Old
Common Stock”) will be automatically and without any action
on the part of the holder thereof reclassified as and converted
into one share of Common Stock (the “New Common
Stock”); provided
that no fractional shares shall be issued as a result thereof, and
that in lieu of the issuance of a fraction of a share to any
shareholder, the Corporation shall pay to such shareholder a cash
payment in the amount equal to such fraction amount of one share of
Common Stock otherwise issuable thereby, multiplied by the average
of the high and low prices of the Common Stock as traded in the
OTCQB market of the OTC Markets Group on the day immediately
following the day such reverse stock split is made effective by the
appropriate securities regulatory authority. Each stock certificate
that, immediately prior to the Effective Time, represented shares
of Old Common Stock shall, from and after the Effective Time,
automatically and without the necessity of presenting the same for
exchange, represent that the number of whole shares of New Common
Stock into which the shares of Old Common Stock represented by such
certificate shall have been reclassified. If more than one Old
Certificate shall be surrendered at one time for the account of the
same shareholder, the number of full shares of New Common Stock for
which New Certificates shall be issued shall be computed on the
basis of the aggregate number of shares represented by the Old
Certificates so surrendered. From and after the Effective Time the
amount of capital represented by the shares of the New Common Stock
into which and for which the shares of the Old Common Stock are
reclassified under the terms hereof shall be the same as the amount
of capital represented by the shares of Old Common Stock so
reclassified, until thereafter reduced or increased in accordance
with applicable law.